vs

Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and C4 Therapeutics, Inc. (CCCC). Click either name above to swap in a different company.

ASCENT INDUSTRIES CO. is the larger business by last-quarter revenue ($11.9M vs $11.0M, roughly 1.1× C4 Therapeutics, Inc.). ASCENT INDUSTRIES CO. runs the higher net margin — -8.8% vs -186.0%, a 177.2% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs 13.3%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs -34.9%).

Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

ACNT vs CCCC — Head-to-Head

Bigger by revenue
ACNT
ACNT
1.1× larger
ACNT
$11.9M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+99.4% gap
CCCC
112.8%
13.3%
ACNT
Higher net margin
ACNT
ACNT
177.2% more per $
ACNT
-8.8%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
-34.9%
ACNT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACNT
ACNT
CCCC
CCCC
Revenue
$11.9M
$11.0M
Net Profit
$-1.0M
$-20.5M
Gross Margin
14.6%
Operating Margin
-21.0%
-210.1%
Net Margin
-8.8%
-186.0%
Revenue YoY
13.3%
112.8%
Net Profit YoY
-1.2%
40.7%
EPS (diluted)
$-0.11
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACNT
ACNT
CCCC
CCCC
Q4 25
$11.9M
$11.0M
Q3 25
$19.7M
$11.2M
Q2 25
$18.7M
$6.5M
Q1 25
$24.7M
$7.2M
Q4 24
$10.5M
$5.2M
Q3 24
$20.9M
$15.4M
Q2 24
$21.5M
$12.0M
Q1 24
$28.0M
$3.0M
Net Profit
ACNT
ACNT
CCCC
CCCC
Q4 25
$-1.0M
$-20.5M
Q3 25
$-2.1M
$-32.2M
Q2 25
$6.3M
$-26.0M
Q1 25
$-2.3M
$-26.3M
Q4 24
$-1.0M
$-34.6M
Q3 24
$-6.2M
$-24.7M
Q2 24
$-926.0K
$-17.7M
Q1 24
$-5.5M
$-28.4M
Gross Margin
ACNT
ACNT
CCCC
CCCC
Q4 25
14.6%
Q3 25
29.7%
Q2 25
26.1%
Q1 25
19.3%
Q4 24
24.3%
Q3 24
14.4%
Q2 24
13.1%
Q1 24
8.3%
Operating Margin
ACNT
ACNT
CCCC
CCCC
Q4 25
-21.0%
-210.1%
Q3 25
-4.1%
-306.4%
Q2 25
-14.4%
-441.0%
Q1 25
-4.2%
-402.9%
Q4 24
-25.4%
-728.4%
Q3 24
-9.4%
-183.9%
Q2 24
-8.6%
-178.6%
Q1 24
-15.5%
-1060.2%
Net Margin
ACNT
ACNT
CCCC
CCCC
Q4 25
-8.8%
-186.0%
Q3 25
-10.6%
-286.4%
Q2 25
33.7%
-402.6%
Q1 25
-9.3%
-363.7%
Q4 24
-9.8%
-667.8%
Q3 24
-29.5%
-160.6%
Q2 24
-4.3%
-147.6%
Q1 24
-19.7%
-933.2%
EPS (diluted)
ACNT
ACNT
CCCC
CCCC
Q4 25
$-0.11
$-0.09
Q3 25
$-0.22
$-0.44
Q2 25
$0.65
$-0.37
Q1 25
$-0.23
$-0.37
Q4 24
$-0.11
$-0.50
Q3 24
$-0.61
$-0.35
Q2 24
$-0.09
$-0.26
Q1 24
$-0.54
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACNT
ACNT
CCCC
CCCC
Cash + ST InvestmentsLiquidity on hand
$57.6M
$74.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$87.0M
$256.6M
Total Assets
$111.9M
$359.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACNT
ACNT
CCCC
CCCC
Q4 25
$57.6M
$74.6M
Q3 25
$58.0M
$58.8M
Q2 25
$60.5M
$78.2M
Q1 25
$14.3M
$51.3M
Q4 24
$16.1M
$55.5M
Q3 24
$8.5M
$59.6M
Q2 24
$3.6M
$73.1M
Q1 24
$1.3M
$89.7M
Total Debt
ACNT
ACNT
CCCC
CCCC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACNT
ACNT
CCCC
CCCC
Q4 25
$87.0M
$256.6M
Q3 25
$87.1M
$154.4M
Q2 25
$89.7M
$174.1M
Q1 25
$91.2M
$195.1M
Q4 24
$93.5M
$216.0M
Q3 24
$94.7M
$242.7M
Q2 24
$101.0M
$247.1M
Q1 24
$102.0M
$258.3M
Total Assets
ACNT
ACNT
CCCC
CCCC
Q4 25
$111.9M
$359.1M
Q3 25
$119.9M
$265.5M
Q2 25
$122.6M
$296.5M
Q1 25
$152.5M
$319.5M
Q4 24
$147.3M
$349.6M
Q3 24
$148.6M
$376.1M
Q2 24
$158.2M
$381.1M
Q1 24
$161.0M
$398.4M
Debt / Equity
ACNT
ACNT
CCCC
CCCC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACNT
ACNT
CCCC
CCCC
Operating Cash FlowLast quarter
$266.0K
$-22.1M
Free Cash FlowOCF − Capex
$-196.0K
FCF MarginFCF / Revenue
-1.7%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-2.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACNT
ACNT
CCCC
CCCC
Q4 25
$266.0K
$-22.1M
Q3 25
$1.3M
$-31.2M
Q2 25
$-1.4M
$-12.1M
Q1 25
$-700.0K
$-33.3M
Q4 24
$8.8M
$-17.9M
Q3 24
$3.4M
$-24.1M
Q2 24
$2.2M
$-5.0M
Q1 24
$263.0K
$-18.1M
Free Cash Flow
ACNT
ACNT
CCCC
CCCC
Q4 25
$-196.0K
Q3 25
$695.0K
$-31.6M
Q2 25
$-1.5M
Q1 25
$-1.0M
Q4 24
$8.4M
$-17.9M
Q3 24
$3.1M
$-24.1M
Q2 24
$1.9M
$-5.2M
Q1 24
$25.0K
FCF Margin
ACNT
ACNT
CCCC
CCCC
Q4 25
-1.7%
Q3 25
3.5%
-281.5%
Q2 25
-8.3%
Q1 25
-4.1%
Q4 24
80.6%
-346.5%
Q3 24
15.1%
-157.2%
Q2 24
9.1%
-43.1%
Q1 24
0.1%
Capex Intensity
ACNT
ACNT
CCCC
CCCC
Q4 25
3.9%
Q3 25
3.1%
3.7%
Q2 25
0.8%
Q1 25
1.3%
Q4 24
3.7%
0.1%
Q3 24
1.3%
0.1%
Q2 24
1.0%
1.6%
Q1 24
0.9%
0.0%
Cash Conversion
ACNT
ACNT
CCCC
CCCC
Q4 25
Q3 25
Q2 25
-0.22×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACNT
ACNT

Other$6.1M52%
Transferred At Point In Time$5.7M48%

CCCC
CCCC

Segment breakdown not available.

Related Comparisons